Recent studies identified a prognostic gene signature (SLC2A1, TNS4, GGTLC1) linked to T cell senescence, which predicts immunotherapy response and poor survival in NSCLC patients. The gene discussed is SLC2A1; the disease is non-small cell lung carcinoma.